A randomized trial of raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy

AIDS Patient Care and STDs

Volumn 26, Issue 9, 2012, Pages 532-540

  Lake, Jordan E ^a   McComsey, Grace A ^b   Hulgan, Todd M ^c   Wanke, Christine A ^d   Mangili, Alexandra ^d   Walmsley, Sharon L ^e   Boger, M Sean ^f   Turner, Ralph R ^g   McCreath, Heather E ^a   Currier, Judith S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g Phase V Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; C REACTIVE PROTEIN; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; LAMIVUDINE; LIPID; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; TENOFOVIR;

ABSENCE OF SIDE EFFECTS; ADULT; AFRICAN AMERICAN; ANTHROPOMETRY; ARTICLE; BODY MASS; BODY SIZE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAABDOMINAL FAT; LIPID BLOOD LEVEL; LIPOHYPERTROPHY; MALE; QUALITY OF LIFE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADIPOSE TISSUE, WHITE; ADULT; BODY SIZE; C-REACTIVE PROTEIN; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPERTROPHY; INTRA-ABDOMINAL FAT; LONGITUDINAL STUDIES; PYRROLIDINONES; QUALITY OF LIFE; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD;

EID: 84865459534     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2012.0135     Document Type: Article

References (29)

1. Crane HM, Grunfeld C, Harrington RD, Uldall KK, Ciechanowski PS, Kitahata MM. Lipoatrophy among HIV-infected patients is associated with higher levels of depression than lipohypertrophy. HIV Med 2008;9:780-786.
2. Falutz J. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy. Nat Clin Pract Endocrinol Metab 2007;3:651-661. (Pubitemid 47294430)
3. Currier J, Scherzer R, Bacchetti P, et al. Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. J Acquir Immune Defic Syndr 2008;48:35-43. (Pubitemid 351600850)
4. Wohl D, Scherzer R, Heymsfield S, et al. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr 2008;48: 44-52. (Pubitemid 351600858)
5. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987;36:54-59. (Pubitemid 17016386)
6. Grunfeld C, Rimland D, Gibert CL, et al. Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immune Defic Syndr 2007;46:283-290. (Pubitemid 350287354)
7. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004;53:2087-2094. (Pubitemid 38970759)
8. Cabrero E, Griffa L, Burgos A. Prevalence and impact of body physical changes in HIV patients treated with highly active antiretroviral therapy: Results from a study on patient and physician perceptions. AIDS Patient Care STDs 2010; 24:5-13.
9. Tien PC, Barron Y, Justman JE, et al. Antiretroviral therapies associated with lipoatrophy in HIV-infected women. AIDS Patient Care STDs 2007;21:297-305. (Pubitemid 46842157)
10. Hawkins T. Appearance-related side effects of HIV-1 treatment. AIDS Patient Care STDs 2006;20:6-18. (Pubitemid 43172777)
11. Jacobson DL, Knox T, Spiegelman D, Skinner S, Gorbach S, Wanke C. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis 2005;40:1837-1845. (Pubitemid 40799956)
12. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009;23:1109-1118.
13. Dube MP, Komarow L, Mulligan K, et al. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr 2007;45:508-514. (Pubitemid 47294922)
14. Pujari SN, Dravid A, Naik E, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr 2005;39:199-202.
15. Mutimura E, Stewart A, Rheeder P, Crowther NJ. Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 46:451-455. (Pubitemid 350098696)
16. Wohl DA, Brown TT. Management of morphologic changes associated with antiretroviral use in HIV-infected patients. J Acquir Immune Defic Syndr 2008;49(Suppl 2):S93-S100.
17. Andany N, Raboud JM, Walmsley S, et al. Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada. HIV Clin Trials 2011;12:89-103.
18. Heath KV, Chan KJ, Singer J, O'Shaughnessy MV, Montaner JS, Hogg RS. Incidence of morphological and lipid abnormalities: Gender and treatment differentials after initiation of first antiretroviral therapy. Int J Epidemiol 2002;31: 1016-1020. (Pubitemid 35446877)
19. Galli M, Veglia F, Angarano G, et al. Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr 2003; 34:58-61. (Pubitemid 37100112)
20. McComsey G, Rightmire A, Wirtz V, Yang R, Mathew M, McGrath D. Changes in body composition with ritonavirboosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: A 96-week randomized, controlled study. Clin Infect Dis 2009;48:1323-1326.
21. Brown TT, Chu H, Wang Z, et al. Longitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapy. AIDS 2007;21: 1731-1738. (Pubitemid 47237560)
22. McComsey GA, Kitch D, Sax PE, et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: Actg Study A5224s. Clin Infect Dis 2001;53:185-196.
23. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravirbased regimen versus continuation of a lopinavir-ritonavirbased regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): TWO multicentre, double-blind, randomised controlled trials. Lancet 2010;375: 396-407.
24. Lennox JL, Dejesus E, Berger DS, et al. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010;55: 39-48.
25. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: A multicentre, double-blind randomised controlled trial. Lancet. Sep 5 2009;374:796-806.
26. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357:2359-2370. (Pubitemid 350223390)
27. Turner R. The impact of recombinant human growth hormone (r-hGH) on body image and health-related quality of life (HRQOL) in patients with HIV-associated adipose redistribution syndrome (HARS)Antiviral Ther 2006;11:L56.
28. Curran A SM, Martinez E, Larrouse M, Podzamezer D, Ocana I, Lonca M, Gatell J, Ribera E, and SPIRAL Study Group Body composition chagnes after switching from protease inhibitors to RAL: SPIRAL LIP substudy. AIDS 2011;26:475-481.
29. Saumoy M OJ, Martinez E, Llibre J, Ribera E, Knobel H, Podzamczer D Comprehensive lipid evaluation in patients switching from PI/r-based cART to a RAL-based cART: The SPIRAL Substudy. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections. February 27-March 2, 2011. Boston, MA: 2011:402.